Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients

BACKGROUND: Trials have not assessed the effect of dalfampridine-extended release (dalfampridine-ER) on health utility. We sought to evaluate the effect of dalfampridine-ER tablets (prolonged-release fampridine in Europe) on health utility in patients with multiple sclerosis (MS) by mapping subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Limone, Brendan L, Sidovar, Matthew F, Coleman, Craig I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699372/
https://www.ncbi.nlm.nih.gov/pubmed/23799913
http://dx.doi.org/10.1186/1477-7525-11-105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699372/
https://www.ncbi.nlm.nih.gov/pubmed/23799913
http://dx.doi.org/10.1186/1477-7525-11-105

Ejemplares similares